6 stories from 5 sources

Drug evidence faces scrutiny as new treatment options emerge

Day’s Recap

Supporting Articles

1:29 PMStat News

STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua

Summary

A failed AstraZeneca trial for Wainua has intensified scrutiny of RNA-based treatments for heart disease and increased pressure on Alnylam. The company is defending the evidence behind its own medicines and arguing that Wainua’s result should not be generalized across the class.

The decisive shift is that Wainua’s failure has weakened confidence in a broader treatment strategy,

Why it matters

One failed trial could raise the evidentiary bar for an entire class of heart disease medicines.

Link to Story

2:30 PMStat News

STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer

Summary

The FDA approved Mimrylo, developed by Protagonist Therapeutics and Takeda, to treat polycythemia vera, a rare blood cancer. The drug represents a new treatment approach for the disease.

The approval gives people with polycythemia vera another therapeutic option beyond existing treatments. Its impact

Why it matters

The decision expands the treatment landscape for patients with a rare blood cancer.

Link to Story

10:35 AMScienceDaily

Common supplements rival antibiotics for severe gum disease

Summary

In a year-long study of patients with severe gum disease, omega-3 supplements combined with low-dose aspirin matched antibiotics in helping about 58% reach the treatment goal. The findings suggest an alternative approach that could reduce antibiotic use in some cases.

The key finding is that an inexpensive anti-inflammatory combination performed as well as antibiotics in

Why it matters

A low-cost non-antibiotic option could reshape periodontal care while helping limit unnecessary antibiotic use.

Link to Story

Other Developments

A curated list of other prominent stories from this day.

10:08 AMBloomberg Markets

Investors Bet on a Hair Loss Treatment Boom

Summary

Drugmakers are developing lotions, pills and longer-lasting injections for pattern hair loss, which affects tens of millions of people in the US. Some candidates could reach the market as early as 2027, attracting investors to a consumer market already supporting substantial spending on hair restoration.

The next shift is from procedural hair restoration toward a broader drug market with more

Why it matters

Hair loss could become a larger chronic-treatment market, expanding both patient choices and drugmakers' consumer health opportunities.

Link to Story

7:00 AMThe Guardian Books

Could this policy fix the care system and slash student debt at the same time?

Summary

The proposal would offer students a 50% reduction in university fees in exchange for a year of work in social care. It aims to address the UK's staffing and funding crisis while reducing graduates' debt burden.

The proposal links two structural problems: a shortage of care workers and the high cost

Why it matters

A tuition-for-care scheme could ease workforce shortages, but it cannot repair social care without improving the jobs themselves.

Link to Story

6:00 AMFinancial Times

Pharma stocks soar as investors seek AI alternatives

Summary

Pharmaceutical stocks have rallied as companies secure pricing agreements with the White House and report encouraging clinical results. The gains suggest investors are looking beyond the technology sector for growth opportunities tied to drug development.

The sector's rebound rests on two concrete changes: reduced political uncertainty over pricing and stronger

Why it matters

Pharma is regaining investor favor as policy risk eases and drug pipelines produce credible results.

Link to Story

Make it yours

Build Your First Pass.

Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!